This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Drug Enforcement Administration (DEA) will move to reclassify cannabis — a historic shift that could have wide ripple effects across the country. Understanding current drug scheduling for cannabis The DEA classifies drugs, substances, and certain chemicals used to make drugs into five distinct categories or “schedules.”
What’s more, synthesized Delta-9 THC is present in many of these products, despite being prohibited in both California’s cannabis and hemp programs. She sees a potential for vape-related lung damage similar to the nationwide outbreak of hundreds of pulmonary injuries, some fatal, that researchers linked to vaping in 2019.
Our lead story addresses the ISO 17065 Accreditation of our PFC program and explains why PFC becoming the first cannabis certification body to have achieved this matters so much. You will also find out how to access the recorded panels from Unity 2021 to catch anything you missed.
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.
Cybin Granted DEA Schedule I Manufacturing License. Drug Enforcement Agency (“DEA”). The DEA license is a federal requirement for any investigators who intend to study, produce, analyze or otherwise work with Schedule I controlled substances. The DEA license is for the Company’s research lab in the Boston area.
The initiative is part of Project Change Lives; Clever Leaves’ $25M product pledge to aid cannabis research in the U.S. The collaboration represents the Company’s first funded study with a research institution in the United States. organization to help advance scientific research into the potential medical benefits of cannabinoids.
Did we ever stop to think that if we could legally utilize the plants in the first place that perhaps we wouldn’t develop terminal illnesses at such a high rate? The FDA refers to this program as the expanded access program on their website. Introducing the Right to Try Act. Sunil Aggarwal was also named in the lawsuit.
Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate. D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted.
We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Program between St. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners .
Researchers believe cannabis contains over 100 unique chemical compounds! Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential.
Drug Enforcement Agency (DEA) to the Alcohol and Tobacco Tax and Trade Bureau (TTB), the Bureau of Alcohol Tobacco Firearms and Explosives (ATF). The bill includes several provisions for additional research to investigate the impact of legalization on public health, driving safety, and similar areas. Research, Training and Prevention.
If passed, the Department of Regulatory Agencies would be required to develop rules that would allow for therapeutic psychedelic programs at licensed healing centers for adults to receive psychedelic treatments by a trained facilitator. Research and Testimonials Point to Psychedelics’ Therapeutic Benefits.
On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation. POPLAR will publish original law and policy research. What barriers exist to conducting psychedelics research?
On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree. The Next Move Is On The DEA. FDA Grants Approval of Epidiolex.
Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. In June 2021, similar measures were passed in Connecticut and Texas, where medical research on psilocybin is now also legal on a statewide level.
” This fee — which is designed to support social equity programs — is required to convert up to three medical cannabis dispensaries into dual medical-recreational facilities. Contingent on reenactments in 2022, specific license caps will be implemented for Virginia’s adult-use cannabis program. Retail stores: 400.
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.
as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Later that year, Doblin sued the DEA for the first time.
According to Dr. Sue Sisley, President of the Scottsdale Research Institute and longtime cannabis researcher, this new study is sorely needed in the community. Veterans are demanding objective cannabis drug developmentresearch, and the state of Michigan is fulfilling our collective obligation to our beloved Veteran community.”.
One year after the United States Department of Agriculture (USDA) issued its final rules on hemp, various states enacted their own regulatory programs. With that research, they created elaborate matrices to compare each mandate. We developed the National Hemp Testing Panel because comprehensive testing is key to the industry’s future.
Dr. Titus has been involved in the development and investment of several industry-leading cannabis and industrial hemp businesses during his most recent career. Dr. Titus developed several prominent cannabis companies, including HempMeds, KannaLife Sciences Inc, and Kannaway, LLC.
To a large extent legalization of adult-use cannabis, including New York’s passage of the Marijuana Regulation and Taxation Act of 2021 (MRTA), has eclipsed other developments in the cannabis sector over the past year. 5940), which allows hemp to be cultivated for research (as opposed to commercial) purposes. ” See 7 U.S.C.
MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices. The full statement. Nair, Ph.D., lead author and MAPS PBC Head of Chemistry, Manufacturing, and Controls. Berra Yazar-Klosinski, Ph.D.
Epidiolex, an FDA-approved medication containing CBD (cannabidiol), has been listed as Schedule 5 by the DEA since June 25th, 2019. Another for of ‘prescribed’ cannabis is Marinol , which is synthetic THC, developed in the 80’s and used for such conditions as Cancer and AIDS. Cannabis is a schedule 1 substance.
. – Today, ahead of the 50th anniversary—on June 17—of when President Richard Nixon declared the “war on drugs,” Representatives Bonnie Watson Coleman (D-NJ) and Cori Bush (D-MO) unveiled the Drug Policy Reform Act (DPRA), alongside the Drug Policy Alliance, which has been a strategic partner on the development of the legislation.
Finally, the resolution recommends that Congress pass legislation to “encourage scientific research into the efficacy, dose, routes of administration, or side effects of commonly used and commercially available cannabis products in the United States.”. The final part of the resolution discusses the need to support research into cannabis.
An Examination of the USDA Hemp Production Program. Testimonies During The House Agriculture Subcommittee On Biotechnology, Horticulture, And Research Addressed FDA Inaction on CBD and Intoxicating Hemp Derivatives. Washington D.C. Today, U.S. That reluctance, in turn, has dampened industry demand for harvested hemp material.”. “In
North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Watch Video: The Press Release. NEWS PROVIDED BY. Numinus Wellness Inc. .
23 Yet this conversion is occurring without regulatory oversight to ensure process standardization, product specification, and accurate third-party testing, all of which are mandated in state-licensed cannabis programs. 22 These non-natural THC-like isomers are difficult to measure and almost impossible to remove from the end product.
Named because it is the result of the joining two different chemical types – a ketone and an amine, ketamine was developed in 1962 as an alternative dissociative anesthetic drug to the potently hallucinogenic phencyclidine, known more commonly as PCP. It was becoming clear that another class of anesthetics was needed.
including building inventory and activating new production capacity along with higher third-party shipping, distribution and warehousing costs, partially offset by payroll subsidies received from the Canadian government in Q1 2022, pursuant to a COVID-19 relief program. Drug Enforcement Administration (the “DEA”), the U.S.
Concrete extraction technicians, researchers, marijuana cultivators, marketers, marijuana processors, cannabis branding, and developers will all have a place in the industry. There are a number of ways that your skills can be used to develop a business. Research Your Competitors.
Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research. One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition.
It’s Russian roulette,” said James Neal-Kababick, director of Flora Research Laboratories, which tested the products. Vaping, in general, has come under increased scrutiny in recent weeks because hundreds of users have developed mysterious lung illnesses, and several have died. Vapes are not covered.
Marijuana and Cannabinoids: Health, Research and Regulatory Considerations (Position Paper). Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. This process should also ensure appropriate funding allocated for this research.
Although research is still underway, the effects of both short- and long-term exposure to pesticides by consuming (i.e., Accordingly, state pesticide programs have tried to provide some clarity to fill the gap left by EPA. pursuant to Drug Enforcement Agency (DEA) or state-level programs). million cars on the road.
To hear more about Steven’s research, what he hopes it will lead to, his predictions for the future of cannabis, how he is helping those most harmed by the war on drugs, and how you can help too, tune in today! SP: Yeah, so I guess right now, with my research, I am actually looking to create a catalog of trichomes. SP: Say that again.
“Our cost savings program is on track to deliver $150 – $200 million of savings within the next 18 months, and we remain committed to our path to profitability by the end of Fiscal 2022, while continuing to invest in an organization that is focused on insights, innovation and gaining momentum in the U.S.
This is a well researched and detailed report and is, we suggest required reading. Research suggests that about one in five people will have an increase in paranoia as a result of the delta-9 THC after consuming cannabis. And that was just the beginning. The Risk of Delta-8 Products with High Delta-9 For Anxiety and Depression.
At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. These cannabis products are used by researchers in the U.S.
29 The Department of Justice alleged that Google had “allow[ed] online Canadian pharmacies to place advertisements through its AdWords program targeting consumers in the United States” and that Google specifically assisted the pharmacies in “optimizing their AdWords advertisements, and improving the effectiveness of their websites.”
Many people in the cannabis industry are convinced that this HHS recommendation to the Drug Enforcement Administration (DEA) means that the DEA will undertake this rescheduling (and fairly quickly, too–which would be a huge departure from its refusal to reschedule back in 2016). if the plant is moved to Schedule III.
The Drug Enforcement Administration (DEA) published its Notice of Proposed Rulemaking (“NOPR”) last week to much fanfare. In my very quick analysis after the rule dropped, I flagged DEA’s statement that it may develop “marijuana-specific controls” in conjunction with rescheduling. Marijuana-specific controls in schedule III?
Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content